Acacia Pharma is a pharmaceutical company engaged in the R&D of supportive care drugs for cancer patients.
Acacia Pharma Ltd., a pharmaceutical company, discovers and develops supportive care drugs. The company focuses on cancer supportive care. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use of prevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer related fatigue, cancer cachexia, and xerostomia. Acacia Pharma Ltd. was incorporated in 2006 and is based in Cambridge, United Kingdom.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 2, 2018 | Debt Financing | $30M | 1 | — | — | Detail |
Feb 21, 2018 | IPO | €40M | — | — | — | Detail |
Sep 3, 2013 | Series B | $23.50M | 5 | F-Prime Capital Novo Holdings | — | Detail |
Mar 31, 2011 | Series A | $10M | 2 | Lundbeckfonden Ventures | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 4, 2020
Cosmo Pharmaceuticals
|
Post-IPO Debt | $25M | Biotechnology | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
F-Prime Capital | Yes | Series B |
Novo Holdings | Yes | Series B |
Hercules Capital | — | Debt Financing |
Eight Roads Ventures | — | Series B |
Gilde Healthcare | — | Series B |
Lundbeckfonden Ventures | — | Series B |
Acacia Pharma has had 1 exits. Acacia Pharma most notable exits include Cosmo Pharmaceuticals
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Mar 23, 2007 | Cosmo Pharmaceuticals | IPO | Biotechnology | Detail |